CV Sciences (CVSI) Depreciation & Amortization (CF) (2013 - 2026)
CV Sciences (CVSI) reported Depreciation & Amortization (CF) of $23000.0 for Q1 2026, down 71.95% on a YoY basis from $82000.0 in Q1 2025, and up 9.52% sequentially from $21000.0 in Q4 2025.
CV Sciences (CVSI) Depreciation & Amortization (CF) (2013 - 2026) Analysis & Trends
CV Sciences (CVSI) has 14 years of Depreciation & Amortization (CF) data on file, last reported at $23000.0 in Q1 2026.
- For the quarter ending Q1 2026, Depreciation & Amortization (CF) fell 71.95% year-over-year to $23000.0; the trailing twelve-month figure through Mar 2026 stood at $133000.0 (down 62.32% YoY), and the FY2025 full-year result was $192000.0, down 42.51% from the prior year.
- Depreciation & Amortization (CF) grew to $23000.0 in Q1 2026, from $21000.0 in the prior quarter.
- In the past five years, Depreciation & Amortization (CF) ranged from a high of $517000.0 in Q1 2022 to a low of $21000.0 in Q4 2025.
- A 5-year average of $104470.6 and a median of $63000.0 in 2022 frame the typical range for Depreciation & Amortization (CF).
- Across the five-year window, Depreciation & Amortization (CF) surged 153.43% in 2022 and tumbled 88.59% in 2023, its largest moves.
- Tracing CVSI's Depreciation & Amortization (CF) over 5 years: stood at $69000.0 in 2022, then declined by 14.49% to $59000.0 in 2023, then soared by 93.22% to $114000.0 in 2024, then plunged by 81.58% to $21000.0 in 2025, then rose by 9.52% to $23000.0 in 2026.
- Business Quant data shows CVSI's Depreciation & Amortization (CF) at $23000.0 in Q1 2026, $21000.0 in Q4 2025, and $31000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Depreciation & Amortization (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | 239.00 Mn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 119.00 Mn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | 1.04 Bn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | 22.60 Mn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | 676.10 Mn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | 7.20 Mn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | 172.00 Mn |
| 10 | CV Sciences | 3.74 Mn | 3.43 Mn | 1.56 Mn | 23,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 23,000.00 |
| Mar 31, 2026 | 23,000.00 |
| Dec 31, 2025 | 21,000.00 |
| Dec 31, 2025 | 21,000.00 |
| Sep 30, 2025 | 31,000.00 |
| Sep 30, 2025 | 31,000.00 |
| Jun 30, 2025 | 58,000.00 |
| Jun 30, 2025 | 58,000.00 |
| Mar 31, 2025 | 82,000.00 |
| Mar 31, 2025 | 82,000.00 |
| Dec 31, 2024 | 114,000.00 |
| Dec 31, 2024 | 114,000.00 |
| Sep 30, 2024 | 81,000.00 |
| Sep 30, 2024 | 81,000.00 |
| Jun 30, 2024 | 76,000.00 |
| Jun 30, 2024 | 76,000.00 |
| Mar 31, 2024 | 63,000.00 |
| Mar 31, 2024 | 63,000.00 |
| Dec 31, 2023 | 59,000.00 |
| Dec 31, 2023 | 59,000.00 |